Advertisement

Hyponatremia pp 145-157 | Cite as

Hyponatremia in Cirrhosis: Evaluation and Treatment

  • Elsa Solà
  • Andrés Cárdenas
  • Pere Ginès
Chapter

Abstract

Hyponatremia is a common complication in patients with cirrhosis that is related to impairment in the renal capacity to eliminate solute-free water. The main pathogenic factor associated with hyponatremia is a non-osmotic hypersecretion of vasopressin which acts in the V2-receptors in the renal collecting ducts. A decrease in serum sodium concentration is associated with an increased risk of hepatic encephalopathy. Hyponatremia is associated with poor prognosis in patients with cirrhosis. There is evidence that hyponatremia also represents a risk factor for liver transplantation, as it is associated with an increased frequency of complications and a decreased short-term survival after transplantation. Classical treatment of hyponatremia is based on fluid restriction, but is poorly effective. The current pharmacological approach to hyponatremia has advanced with vaptans, a new family of drugs which antagonize V2-receptors in the renal collecting ducts. Short-term treatment with vaptans is associated with an increase in serum sodium concentration and improvement in health-related quality of life. Nevertheless, information on the use of vaptans in cirrhosis is limited and further long-term studies are needed.

Keywords

Hepatic Encephalopathy Serum Sodium Serum Sodium Level Serum Sodium Concentration Await Liver Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ginès P, Cárdenas A, Schrier R. Liver disease and the kidney. In: Schrier R, editor. Diseases of the kidney and urinary tract. 8th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 2179–205.Google Scholar
  2. 2.
    Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Ginès P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998;28:851–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance and management. Hepatology. 2008;48:1002–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Ginès P, Angeli P, Lenz K, Möller S, Moore K, Moreau R, et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53:397–417.CrossRefGoogle Scholar
  6. 6.
    Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol. 2006;4:1385–94.PubMedCrossRefGoogle Scholar
  7. 7.
    Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006;44:1535–42.PubMedCrossRefGoogle Scholar
  8. 8.
    Biggins S, Rodriguez HJ, Bachetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41:32–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Londoño MC, Cardenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut. 2007;56:1283–90.PubMedCrossRefGoogle Scholar
  10. 10.
    Londoño MC, Guevara M, Rimola A, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006;130:1135–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Dawwas MF, Lewsey JD, Neuberger J, et al. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007;13:1115–24.PubMedCrossRefGoogle Scholar
  12. 12.
    Kim WR, Biggins SW, Kremers WK, Wiesner RH, Kamath PS, Benson JT, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359:1018–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Biggins SW, Kim WR, Terrault NA, Saab S, Balan V, Schiano T, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006;130:1652–60.PubMedCrossRefGoogle Scholar
  14. 14.
    Ruf AE, Kremers WK, Chavez LL, Descalzi VI, Podesta LG, Villamil FG. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl. 2005;11:336–43.PubMedCrossRefGoogle Scholar
  15. 15.
    Pereira G, Guevara M, Fagundes C, Solá E, Rodríguez E, Fernández J, et al. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J Hepatol. 2012;56:1040–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Ishikawa S, Schrier RW. Pathogenesis of hyponatremia: the role of arginine vasopressin. In: Ginès P, Arroyo V, Rodes J, Schrier R, editors. Ascites and renal dysfunction in liver disease. 2nd ed. Oxford: Blackwell; 2005. p. 305–14.Google Scholar
  17. 17.
    Thibonnier M, Conarty DM, Preston JA, et al. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol. 1998;449:251–76.PubMedCrossRefGoogle Scholar
  18. 18.
    Kwon TH, Hager H, Nejsum LN, et al. Physiology and pathophysiology of renal aquaporins. Semin Nephrol. 2001;21:231–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Nielsen S, Frokiaer J, Marples D, et al. Aquaporins in the kidney: from molecules to medicine. Physiol Rev. 2002;82:205–44.PubMedGoogle Scholar
  20. 20.
    Elhassan EA, Schrier RW. Hyponatremia: diagnosis, complications, and management including V2 receptor antagonists. Curr Opin Nephrol Hypertens. 2011;20:161–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Guevara M, Baccaro ME, Torre A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: a prospective study with time-dependent analysis. Am J Gastroenterol. 2009;104:1382–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–46.PubMedCrossRefGoogle Scholar
  23. 23.
    Guevara M, Baccarro ME, Rios J, et al. Risk factors for hepatic encephalopathy in patients with cirrhosis and refractory ascites: relevance of serum sodium concentration. Liver Int. 2010;30:1137–42.PubMedCrossRefGoogle Scholar
  24. 24.
    Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut. 2008;57:1156–65.PubMedCrossRefGoogle Scholar
  25. 25.
    Córdoba J, García-Martinez R, Simón-Talero M. Hyponatremic and hepatic encephalopathies: similarities, differences and coexistence. Metab Brain Dis. 2010;25:73–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: course, predictive factors and prognosis. Hepatology. 1994;20:1495–501.PubMedCrossRefGoogle Scholar
  27. 27.
    Ginès A, Escorsell A, Ginès P, Saló J, Jiménez W, Inglada L, et al. Incidence, predictive factors, and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 1993;105:229–36.PubMedGoogle Scholar
  28. 28.
    Solà E, Guevara M, Rodriguez E, Barreto R, Pavesi M, Arroyo V, et al. Hyponatremia is a major factor of the impaired health-related quality of life in patients with cirrhosis and ascites. J Hepatol. 2012;57:1199–206.CrossRefGoogle Scholar
  29. 29.
    Jalan R, Mookerjee R, Cheshire L, Williams R, et al. Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial. J Hepatol. 2007;46:232A.CrossRefGoogle Scholar
  30. 30.
    McCormick PA, Mistry P, Kaye G, Burroughs AK, McIntyre N. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut. 1990;31:204–7.PubMedCrossRefGoogle Scholar
  31. 31.
    Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet. 2008;371:1624–32.PubMedCrossRefGoogle Scholar
  32. 32.
    Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology. 2003;37:182–91.PubMedCrossRefGoogle Scholar
  33. 33.
    Gerbes AL, Gulberg V, Ginès P, et al. VPA study group. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology. 2003;124:933–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355:2099–112.PubMedCrossRefGoogle Scholar
  35. 35.
    Ginès P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008;48:204–13.PubMedCrossRefGoogle Scholar
  36. 36.
    Cárdenas A, Ginès P, Marotta P, et al. The safety and efficacy of tolvaptan, an oral vasopressin antagonist in the treatment of hyponatremia in cirrhosis. J Hepatol. 2012;56:571–8.PubMedCrossRefGoogle Scholar
  37. 37.
    O'Leary JG, Davis GL. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transpl. 2009;15:1325–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Wong F, Ginès P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol. 2010;53:283–90.PubMedCrossRefGoogle Scholar
  39. 39.
    Wong F, Watson H, Gerbes A, et al. Satavaptan for the management of ascites in cirrhosis. Efficacy and safety across the spectrum of ascites severity. Gut. 2012;61:108–16.PubMedCrossRefGoogle Scholar
  40. 40.
    Okita K, Sakaida I, Okada M, Kaneko A, Chayama K, Kato M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol. 2010;45:979–87.PubMedCrossRefGoogle Scholar
  41. 41.
    Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21:705–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Elsa Solà
    • 1
    • 4
  • Andrés Cárdenas
    • 2
    • 3
    • 4
  • Pere Ginès
    • 1
    • 4
  1. 1.Liver UnitHospital Clinic de Barcelona, Institut d’Investigacions Biomèdiques August Pi-Sunyer (IDIBAPS)BarcelonaSpain
  2. 2.GI UnitHospital Clinic de BarcelonaBarcelonaSpain
  3. 3.Endoscopy Unit, Institute of Digestive DiseasesHospital Clinic de BarcelonaBarcelonaSpain
  4. 4.University of Barcelona School of MedicineBarcelonaSpain

Personalised recommendations